APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pseudomonas Aeruginosa Pneumonia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pseudomonas Aeruginosa Pneumonia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025176 pages

Choose your research edition.

Industry ResearchPseudomonas Aeruginosa Pneumonia Drug Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Pseudomonas Aeruginosa Pneumonia Drug Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Pseudomonas Aeruginosa Pneumonia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pseudomonas Aeruginosa Pneumonia Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pseudomonas Aeruginosa Pneumonia Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pseudomonas Aeruginosa Pneumonia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pseudomonas Aeruginosa Pneumonia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pseudomonas Aeruginosa Pneumonia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pseudomonas Aeruginosa Pneumonia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pseudomonas Aeruginosa Pneumonia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pseudomonas Aeruginosa Pneumonia Drug include Polyphor Ltd, MedImmune LLC, Emergent BioSolutions Inc and Aridis Pharmaceuticals LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pseudomonas Aeruginosa Pneumonia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pseudomonas Aeruginosa Pneumonia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pseudomonas Aeruginosa Pneumonia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pseudomonas Aeruginosa Pneumonia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pseudomonas Aeruginosa Pneumonia Drug Segment by Company

Polyphor Ltd

MedImmune LLC

Emergent BioSolutions Inc

Aridis Pharmaceuticals LLC

Pseudomonas Aeruginosa Pneumonia Drug Segment by Type

Aerucin

Panobacumab

MEDI-3902

EV-035

Others

Pseudomonas Aeruginosa Pneumonia Drug Segment by Application

Hospital

Clinic

Others

Pseudomonas Aeruginosa Pneumonia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pseudomonas Aeruginosa Pneumonia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pseudomonas Aeruginosa Pneumonia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pseudomonas Aeruginosa Pneumonia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pseudomonas Aeruginosa Pneumonia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pseudomonas Aeruginosa Pneumonia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pseudomonas Aeruginosa Pneumonia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pseudomonas Aeruginosa Pneumonia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pseudomonas Aeruginosa Pneumonia Drug Industry Trends Table 2. Pseudomonas Aeruginosa Pneumonia Drug Industry Drivers Table 3. Pseudomonas Aeruginosa Pneumonia Drug Industry Opportunities and Challenges Table 4. Pseudomonas Aeruginosa Pneumonia Drug Industry Restraints Table 5. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Manufacturers Table 9. Global Pseudomonas Aeruginosa Pneumonia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pseudomonas Aeruginosa Pneumonia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pseudomonas Aeruginosa Pneumonia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pseudomonas Aeruginosa Pneumonia Drug Manufacturers, Product Type & Application Table 13. Global Pseudomonas Aeruginosa Pneumonia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pseudomonas Aeruginosa Pneumonia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aerucin Table 17. Major Manufacturers of Panobacumab Table 18. Major Manufacturers of MEDI-3902 Table 19. Major Manufacturers of EV-035 Table 20. Major Manufacturers of Others Table 21. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Type (2021-2026) Table 25. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Type (2027-2032) Table 26. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Type (2021-2026) Table 30. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Application (2021-2026) Table 38. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Application (2027-2032) Table 39. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Application (2021-2026) Table 43. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Application (2027-2032) Table 44. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Region (2021-2026) Table 47. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Region (2021-2026) Table 65. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Region (2027-2032) Table 66. Polyphor Ltd Company Information Table 67. Polyphor Ltd Business Overview Table 68. Polyphor Ltd Pseudomonas Aeruginosa Pneumonia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Polyphor Ltd Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio Table 70. Polyphor Ltd Recent Development Table 71. MedImmune LLC Company Information Table 72. MedImmune LLC Business Overview Table 73. MedImmune LLC Pseudomonas Aeruginosa Pneumonia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. MedImmune LLC Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio Table 75. MedImmune LLC Recent Development Table 76. Emergent BioSolutions Inc Company Information Table 77. Emergent BioSolutions Inc Business Overview Table 78. Emergent BioSolutions Inc Pseudomonas Aeruginosa Pneumonia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Emergent BioSolutions Inc Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio Table 80. Emergent BioSolutions Inc Recent Development Table 81. Aridis Pharmaceuticals LLC Company Information Table 82. Aridis Pharmaceuticals LLC Business Overview Table 83. Aridis Pharmaceuticals LLC Pseudomonas Aeruginosa Pneumonia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Aridis Pharmaceuticals LLC Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio Table 85. Aridis Pharmaceuticals LLC Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. Pseudomonas Aeruginosa Pneumonia Drug Distributors List Table 89. Pseudomonas Aeruginosa Pneumonia Drug Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Pseudomonas Aeruginosa Pneumonia Drug Product Image Figure 2. Global Pseudomonas Aeruginosa Pneumonia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pseudomonas Aeruginosa Pneumonia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pseudomonas Aeruginosa Pneumonia Drug Sales (2021-2032) & (K Units) Figure 5. Global Pseudomonas Aeruginosa Pneumonia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pseudomonas Aeruginosa Pneumonia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aerucin Image Figure 9. Panobacumab Image Figure 10. MEDI-3902 Image Figure 11. EV-035 Image Figure 12. Others Image Figure 13. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Type (2021-2032) Figure 16. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Application (2021-2032) Figure 25. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Country (2021-2032) Figure 42. China Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Pseudomonas Aeruginosa Pneumonia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Pseudomonas Aeruginosa Pneumonia Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Pseudomonas Aeruginosa Pneumonia Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Aerucin
  • Panobacumab
  • MEDI-3902
  • EV-035
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Polyphor Ltd
  • MedImmune LLC
  • Emergent BioSolutions Inc
  • Aridis Pharmaceuticals LLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pseudomonas Aeruginosa Pneumonia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pseudomonas Aeruginosa Pneumonia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pseudomonas Aeruginosa Pneumonia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pseudomonas Aeruginosa Pneumonia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pseudomonas Aeruginosa Pneumonia Drug Market Dynamics
  1. 2.1 Pseudomonas Aeruginosa Pneumonia Drug Industry Trends
  2. 2.2 Pseudomonas Aeruginosa Pneumonia Drug Industry Drivers
  3. 2.3 Pseudomonas Aeruginosa Pneumonia Drug Industry Opportunities and Challenges
  4. 2.4 Pseudomonas Aeruginosa Pneumonia Drug Industry Restraints
3 Pseudomonas Aeruginosa Pneumonia Drug Market by Manufacturers
  1. 3.1 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pseudomonas Aeruginosa Pneumonia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pseudomonas Aeruginosa Pneumonia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pseudomonas Aeruginosa Pneumonia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pseudomonas Aeruginosa Pneumonia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Pseudomonas Aeruginosa Pneumonia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pseudomonas Aeruginosa Pneumonia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pseudomonas Aeruginosa Pneumonia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pseudomonas Aeruginosa Pneumonia Drug Tier 1, Tier 2, and Tier 3
4 Pseudomonas Aeruginosa Pneumonia Drug Market by Type
  1. 4.1 Pseudomonas Aeruginosa Pneumonia Drug Type Introduction
  2. 4.1.1 Aerucin
  3. 4.1.2 Panobacumab
  4. 4.1.3 MEDI-3902
  5. 4.1.4 EV-035
  6. 4.1.5 Others
  7. 4.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type
  8. 4.2.1 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type
  12. 4.3.1 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Type (2021-2032)
5 Pseudomonas Aeruginosa Pneumonia Drug Market by Application
  1. 5.1 Pseudomonas Aeruginosa Pneumonia Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application
  6. 5.2.1 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Pseudomonas Aeruginosa Pneumonia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application
  10. 5.3.1 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Application (2021-2032)
6 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region
  1. 6.1 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pseudomonas Aeruginosa Pneumonia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Pseudomonas Aeruginosa Pneumonia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region
  1. 7.1 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region
  2. 7.1.1 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Pseudomonas Aeruginosa Pneumonia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032)
  8. 7.2.2 North America Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pseudomonas Aeruginosa Pneumonia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Polyphor Ltd
  2. 8.1.1 Polyphor Ltd Company Information
  3. 8.1.2 Polyphor Ltd Business Overview
  4. 8.1.3 Polyphor Ltd Pseudomonas Aeruginosa Pneumonia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Polyphor Ltd Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio
  6. 8.1.5 Polyphor Ltd Recent Developments
  7. 8.2 MedImmune LLC
  8. 8.2.1 MedImmune LLC Company Information
  9. 8.2.2 MedImmune LLC Business Overview
  10. 8.2.3 MedImmune LLC Pseudomonas Aeruginosa Pneumonia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 MedImmune LLC Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio
  12. 8.2.5 MedImmune LLC Recent Developments
  13. 8.3 Emergent BioSolutions Inc
  14. 8.3.1 Emergent BioSolutions Inc Company Information
  15. 8.3.2 Emergent BioSolutions Inc Business Overview
  16. 8.3.3 Emergent BioSolutions Inc Pseudomonas Aeruginosa Pneumonia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Emergent BioSolutions Inc Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio
  18. 8.3.5 Emergent BioSolutions Inc Recent Developments
  19. 8.4 Aridis Pharmaceuticals LLC
  20. 8.4.1 Aridis Pharmaceuticals LLC Company Information
  21. 8.4.2 Aridis Pharmaceuticals LLC Business Overview
  22. 8.4.3 Aridis Pharmaceuticals LLC Pseudomonas Aeruginosa Pneumonia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aridis Pharmaceuticals LLC Pseudomonas Aeruginosa Pneumonia Drug Product Portfolio
  24. 8.4.5 Aridis Pharmaceuticals LLC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pseudomonas Aeruginosa Pneumonia Drug Value Chain Analysis
  2. 9.1.1 Pseudomonas Aeruginosa Pneumonia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pseudomonas Aeruginosa Pneumonia Drug Production Mode & Process
  6. 9.2 Pseudomonas Aeruginosa Pneumonia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pseudomonas Aeruginosa Pneumonia Drug Distributors
  9. 9.2.3 Pseudomonas Aeruginosa Pneumonia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst